Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts.

Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts.

<h4>Background</h4>Liver fibrosis is one of the cardinal clinical features of chronic hepatitis C (CHC). However, the mechanisms underlying the evolution and reversion of liver fibrosis after hepatitis C virus (HCV) eradication and their relationship with clinical outcomes and metabolic...

Full description

Bibliographic Details
Main Authors:	Karin Yamataka, Po-Sung Chu, Yuzo Koda, Nobuhito Taniki, Rei Morikawa, Aya Yoshida, Fumie Noguchi, Ryosuke Kasuga, Takaya Tabuchi, Hirotoshi Ebinuma, Takanori Kanai, Nobuhiro Nakamoto
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0276925

Similar Items

Vulnerability to recurrent episodes of acute decompensation/acute-on-chronic liver failure characterizes those triggered by indeterminate precipitants in patients with liver cirrhosis.
by: Hitomi Hoshi, et al.
Published: (2021-01-01)

IL-15-producing splenic B cells play pathogenic roles in the development of autoimmune hepatitis
by: Sota Fujimori, et al.
Published: (2023-07-01)

CLIF‐C Organ Failure Score and Liver Volume Predict Prognosis in Steroid‐Treated Severe Acute Autoimmune Hepatitis
by: Akihiko Ikura, et al.
Published: (2020-07-01)

Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study
by: Shunsuke Shiba, et al.
Published: (2020-03-01)

Liver Fibrosis Markers Improve Prediction of Outcome in Non‐Acetaminophen‐Associated Acute Liver Failure
by: Aya Ugamura, et al.
Published: (2018-11-01)

The gut-liver axis in hepatobiliary diseases
by: Masataka Ichikawa, et al.
Published: (2024-01-01)

CCR9 axis inhibition enhances hepatic migration of plasmacytoid DCs and protects against liver injury
by: Yuzo Koda, et al.
Published: (2022-09-01)

Myeloid TLR4 signaling promotes post-injury withdrawal resolution of murine liver fibrosis
by: Yoichi Takimoto, et al.
Published: (2023-03-01)

On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.
by: Po-Sung Chu, et al.
Published: (2017-01-01)

Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C.
by: Po-sung Chu, et al.
Published: (2015-01-01)

Hepatic Adenosine Triphosphate Reduction Through the Short‐Chain Fatty Acids–Peroxisome Proliferator‐Activated Receptor γ–Uncoupling Protein 2 Axis Alleviates Immune‐Mediated Acute Hepatitis in Inulin‐Supplemented Mice
by: Akihiro Yamaguchi, et al.
Published: (2021-09-01)

Detection of bacterial DNA by in situ hybridization in patients with decompensated liver cirrhosis
by: Shingo Usui, et al.
Published: (2017-10-01)

Sitafloxacin for Third-Line <i>Helicobacter pylori</i> Eradication: A Systematic Review
by: Toshihiro Nishizawa, et al.
Published: (2021-06-01)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals
by: Silvia Molina-Carrión, et al.
Published: (2020-07-01)

Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control
by: Mohamed Mohei El Badry, et al.
Published: (2020-11-01)

Role of Toll-like receptors in immune activation and tolerance in the liver
by: Nobuhiro eNakamoto, et al.
Published: (2014-05-01)

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
by: Naoki Kawagishi, et al.
Published: (2018-01-01)

Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy
by: M.G. Deneke, et al.
Published: (2014-01-01)

Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan
by: Tatsunori Hanai, et al.
Published: (2021-08-01)

Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals
by: Tatsuya Minami, et al.
Published: (2021-06-01)

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
by: Kazuto Tajiri, et al.
Published: (2023-05-01)

HCV eradication in people living with HIV: the final countdown?
by: A. De Vito, et al.
Published: (2021-02-01)

Macrophages and dendritic cells emerge in the liver during intestinal inflammation and predispose the liver to inflammation.
by: Yohei Mikami, et al.
Published: (2014-01-01)

Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents
by: Hae Won Yoo, et al.
Published: (2022-01-01)

Letter to the editor: Successful eradication of HCV by short-course DAAs in HCV-Positive donor to HCV-Negative recipient during Haplo-HSCT
by: Yuh-Ching Gau, et al.
Published: (2020-11-01)

Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis
by: Masataka Ichikawa, et al.
Published: (2023-06-01)

Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control
by: Pierre Nahon, et al.
Published: (2021-01-01)

Special Issue “Chronic HCV Infection: Clinical Advances and Eradication Perspectives”
by: Maria Carla Liberto, et al.
Published: (2022-01-01)

B-type natriuretic peptide (BNP) in HCV-positive Egyptian patients: the impact of HCV eradication on plasma BNP levels
by: Ali Nada, et al.
Published: (2021-07-01)

Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals
by: Federica Vernuccio, et al.
Published: (2022-05-01)

Impact of HCV eradication following direct-acting antivirals on liver stiffness measurement: a prospective longitudinal study
by: Ahmed El Ray, et al.
Published: (2023-02-01)

ERADICATION OF HCV INFECTION IN PATIENTS WITH LIVER CIRRHOSIS: FACTOR OF CANCER PREVENTION OR CARCINOGENESIS?
by: N. A. Malinina, et al.
Published: (2019-06-01)

Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience
by: Andrea Marino, et al.
Published: (2021-12-01)

Predictive plasma biomarkers of long-term increase in hepatic steatosis index after HCV eradication in HIV/HCV-coinfected patients
by: Rubén Martín-Escolano, et al.
Published: (2023-08-01)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
by: Óscar Brochado, et al.
Published: (2021-03-01)

Enrichment of type I interferon signaling in colonic group 2 innate lymphoid cells in experimental colitis
by: Emi Irie, et al.
Published: (2022-10-01)

Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study
by: Martina Spaziante, et al.
Published: (2021-07-01)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
by: Atsushi Hosui, et al.
Published: (2021-12-01)

Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients
by: Beatriz Álvarez, et al.
Published: (2020-06-01)

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradicationKey points
by: Pierre Nahon, et al.
Published: (2019-12-01)